Actively Recruiting
Multimodal Analysis of Endomyocardial Biopsies for Molecular and Immune Profiling in Myocardial Diseases
Led by University Hospital, Essen · Updated on 2026-01-22
216
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating molecular markers and immune signaling molecules in various heart muscle diseases including cardiomyopathies, myocarditis, cardiac amyloidosis, and the post-heart transplantation course. This observational study aims to improve diagnosis and therapy by identifying specific molecular profiles such as proteome, lipidome, and metabolome changes associated with these conditions. Participants who are already scheduled to receive an endomyocardial biopsy as part of their regular medical care will be included. An additional biopsy sample will be collected for research purposes, which will be analyzed using multi-omics methods, immune signaling analysis, and nuclear cardiology techniques. These analyses seek to detect genetic mutations, inflammatory gene patterns, and protein alterations, and results will be compared to clinical parameters and biomarkers. During the study, participants will undergo the biopsy procedure along with their routine clinical care. Researchers will measure spatial molecular profiles and immune signaling at the start and follow participants for up to one year. Secondary outcomes include tracer uptake analysis in cardiac amyloidosis. The study is observational and involves no experimental treatments, focusing instead on collecting and analyzing biopsy samples to better understand myocardial diseases.
CONDITIONS
Brief Title
Multimodal Analysis of Endomyocardial Biopsies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged >18 years with a clinical indication for endomyocardial biopsy.
- Patients capable of providing informed consent who have signed the consent form for participation in the study.
You will not qualify if you...
- Patients without a clinical indication for endomyocardial biopsy (EMB).
- Pregnant individuals.
- Patients incapable of providing informed consent.
- Women of childbearing potential who are not using adequate contraception.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of biopsy procedure
Participants undergo an additional endomyocardial biopsy sample collection alongside their clinically indicated biopsy for molecular and immune profiling analyses.
1 visit (in-person)
Duration - Up to 1 year
Participants are monitored with correlation of biopsy results to clinical parameters and biomarkers for up to 1 year.
Follow-up visits as part of routine clinical care
Trial Site Locations
Total: 1 location
1
Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University Hospital Essen, Germany
Essen, North Rhine-Westphalia, Germany, 45147
Actively Recruiting
Research Team
L
Lars Michel, PD Dr. med.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here